PT-141 (bremelanotide) carries a formal FDA contraindication in patients with known cardiovascular disease or uncontrolled hypertension. In controlled trials, the 1.75 mg subcutaneous dose transiently raised mean systolic blood pressure by approximately 3 mmHg and lowered heart rate by roughly 2 bpm — effects that resolve within 12 hours but pose disproportionate risk in patients with compromised cardiac reserve.
How Does PT-141's Mechanism Produce Hemodynamic Effects?
PT-141 is a cyclic heptapeptide melanocortin receptor agonist acting primarily at MC3R and MC4R in hypothalamic and limbic circuits. MC4R activation in the central nervous system drives sympathetic outflow, which accounts for the transient pressor response observed post-dose. This centrally mediated vasoconstriction is mechanistically distinct from the peripheral vasodilation produced by PDE5 inhibitors.
Unlike sildenafil or tadalafil, PT-141 does not act on vascular smooth muscle directly. Its hemodynamic footprint originates upstream in the hypothalamus, where MC4R-coupled sympathetic tone elevation increases peripheral vascular resistance. The blood pressure rise is therefore not attenuated by nitrate co-administration in the same way PDE5 inhibitor interactions are — a clinically important distinction.
MC1R and MC3R are also engaged at therapeutic concentrations. MC1R activation contributes to the flushing and hyperpigmentation seen in some patients. MC3R stimulation in the arcuate nucleus may modulate energy balance pathways, though this is not considered clinically significant at the 1.75 mg approved dose.
What Do the RECONNECT Phase 3 Trials Show About Blood Pressure?
The RECONNECT pivotal studies and the FDA's multidisciplinary review (NDA 210557) document a mean systolic increase of approximately 3 mmHg and a mean diastolic increase of approximately 3 mmHg within the 0–4 hour post-dose window, with full resolution by 12 hours. No cumulative blood pressure elevation was observed with repeated as-needed dosing over 52 weeks.
Ambulatory blood pressure monitoring in a dedicated pharmacodynamic study confirmed these findings in a randomized, double-blind, placebo-controlled parallel-arm design. A small subset of participants showed transient systolic readings exceeding 150 mmHg post-dose. This signal drove the FDA's decision to contraindicate use in patients with pre-existing uncontrolled hypertension.
Heart rate decreased by a mean of approximately 2 bpm concurrently with the blood pressure rise, consistent with a baroreflex-mediated response rather than direct chronotropic suppression. This reflex bradycardia is generally inconsequential in healthy subjects but may be clinically relevant in patients on rate-limiting agents such as beta-blockers or non-dihydropyridine calcium channel blockers.
What Are the FDA-Labelled Cardiovascular Contraindications?
The Vyleesi (bremelanotide) prescribing information lists two absolute cardiovascular contraindications: (1) known cardiovascular disease and (2) uncontrolled hypertension. The label additionally states that PT-141 is "not recommended" for patients at high cardiovascular risk — a softer but clinically meaningful caution covering conditions such as recent myocardial infarction, unstable angina, and severe heart failure.
The distinction between "contraindicated" and "not recommended" is operationally important. Patients with controlled, stable hypertension on antihypertensive therapy are not formally contraindicated but fall into the "not recommended for high-risk" category. Clinicians must individually assess whether a 3 mmHg transient pressor response is acceptable given the patient's baseline cardiovascular reserve.
Severe renal impairment (CrCl below 30 mL/min) is a separate contraindication on the label, relevant because reduced renal clearance prolongs bremelanotide exposure and may amplify the hemodynamic effect duration. Patients with cardiorenal syndrome therefore carry compounded risk from both pathways.
Which Cardiovascular Drug Interactions Are Clinically Significant?
The most consequential labeled interaction is with naltrexone: co-administration reduces bremelanotide bioavailability by approximately 35%, which is pharmacokinetically relevant but not a direct cardiovascular safety concern. Of greater cardiovascular relevance is the theoretical additive pressor risk when PT-141 is combined with vasoconstrictive agents, stimulants, or drugs that blunt baroreflex sensitivity.
Unlike PDE5 inhibitors, PT-141 does not potentiate nitrate-induced hypotension. However, patients on antihypertensive regimens — particularly those with tightly controlled blood pressure near target — may experience clinically meaningful excursions above their therapeutic range during the 0–4 hour post-dose window. Monitoring blood pressure at first administration is a reasonable precaution in this population.
No formal drug interaction studies have been published examining PT-141 alongside ACE inhibitors, angiotensin receptor blockers, or diuretics in patients with established cardiovascular disease. This evidence gap represents a meaningful limitation in current safety characterization for the comorbid population.
What Is the Broader Adverse Event Profile Relevant to Cardiac Patients?
Across the clinical development program, the most common adverse events were nausea, flushing, headache, and injection site reactions — occurring at rates of 40%, 20%, 11%, and 5% respectively versus under 2% for placebo. No serious cardiovascular adverse events were attributed to bremelanotide in the RECONNECT trials, though the enrolled population was screened to exclude cardiovascular disease.
Nausea is the dominant tolerability concern and is mechanistically linked to MC4R activation in the dorsal vagal complex. In patients with cardiac comorbidities, severe nausea can trigger vagally mediated bradycardia or hypotension — a secondary cardiovascular risk not captured in the primary hemodynamic endpoints of the pivotal trials.
Flushing reflects peripheral vasodilation mediated partly through MC1R. In patients with coronary artery disease, episodes of flushing-associated vasodilation may theoretically precipitate demand ischemia if accompanied by reflex tachycardia. No such events were reported in the clinical trial database, but this remains a theoretical concern warranting clinical judgment.
Safety Summary and Contraindication Reference
PT-141 is formally contraindicated in patients with known cardiovascular disease or uncontrolled hypertension, and is not recommended for those at high cardiovascular risk. The hemodynamic signal — a transient ~3 mmHg systolic rise resolving within 12 hours — is modest in healthy subjects but potentially unsafe in patients with reduced cardiac reserve, recent acute coronary events, or tightly controlled hypertension.
Clinicians should apply the following contraindication framework before considering PT-141 in any patient with cardiovascular history. Absolute contraindications per the FDA label include known cardiovascular disease and uncontrolled hypertension. High-risk cautions cover recent myocardial infarction within 6 months, unstable or refractory angina, NYHA Class III–IV heart failure, and severe aortic stenosis.
Use with close monitoring may be appropriate in patients with controlled hypertension on stable antihypertensive therapy, mild-to-moderate chronic kidney disease, or concurrent use of sympathomimetic agents. The critical evidence gap is that no dedicated cardiovascular outcomes data exist for patients with established CVD, as all pivotal trial populations excluded this group.
The 52-week open-label extension of the RECONNECT studies confirmed no cumulative cardiovascular signal in the studied population. However, that population was cardiovascularly screened and does not represent the comorbid patients most likely to be encountered in clinical practice. Extrapolating the clean long-term safety record to patients with cardiovascular disease is not supported by available evidence.
What Evidence Gaps Remain as of 2026?
As of 2026, no prospective trial has enrolled patients with established cardiovascular disease to evaluate PT-141 safety in that population. The entire clinical evidence base derives from studies that excluded cardiovascular comorbidities. Post-marketing pharmacovigilance data have not been published in peer-reviewed form, leaving a critical evidence vacuum for the highest-risk patients.
The MC4R agonist class is receiving renewed research interest in the context of obesity pharmacotherapy, and cardiovascular safety data from those programs may eventually inform bremelanotide risk characterization. However, receptor selectivity profiles differ substantially between compounds, and cross-class extrapolation carries significant uncertainty.
Dedicated pharmacodynamic studies in patients with controlled hypertension — measuring 24-hour ambulatory blood pressure, baroreflex sensitivity, and endothelial function — would substantially clarify the risk-benefit calculus. Until such data exist, the FDA label's contraindication and high-risk caution represent the most defensible clinical boundary. What Does the 2026 Clinical Evidence Actually Show for BPC-157 in Shoulder Rotator Cuff Tears?